Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis

[1]  C. Volpi,et al.  Targeting metabotropic glutamate receptors for the treatment of neuroinflammation , 2018, Current opinion in pharmacology.

[2]  T. Salt,et al.  Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors , 2017, Neuropharmacology.

[3]  P. Girardi,et al.  Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia , 2015, Scientific Reports.

[4]  D. McKinzie,et al.  Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia , 2015, Biological Psychiatry.

[5]  Bita Moghaddam,et al.  A Mechanistic Approach to Preventing Schizophrenia in At-Risk Individuals , 2013, Neuron.

[6]  R. Schwarcz,et al.  Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.

[7]  Bita Moghaddam,et al.  From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment , 2012, Neuropsychopharmacology.

[8]  R. Hoffman,et al.  Symptom Assessment in Schizophrenic Prodromal States , 2004, Psychiatric Quarterly.

[9]  G. Aghajanian,et al.  Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. , 2000, The Journal of pharmacology and experimental therapeutics.

[10]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.